Our take
ARxIUM's robot is RIVA, a fully automated system that prepares hazardous and non-hazardous IV syringes and bags while supporting USP 797 and USP 800 requirements. ARxIUM says RIVA had prepared more than 19 million doses by April 2026.3,4
Around RIVA it sells unit-dose packagers, vial fillers, central fill systems, dispensing cabinets, and inventory software, so it suits hospital and health system pharmacies that want one automation partner. Prices are not published.1,3
Scores by criterion
Pricing transparency, 3.0: ARxIUM lists no prices and asks buyers to request a consultation or talk to an expert.1
Product maturity, 8.0: ARxIUM says it has worked in pharmacy automation for more than 30 years. RIVA is North American safety listed and CE marked and keeps an electronic audit trail for every dose.2,3
Deployment evidence, 7.5: RIVA passed 19 million doses in April 2026, and in September 2026 Prinses Máxima Centrum in the Netherlands passed one million sterile doses compounded with RIVA.4
Company durability, 6.5: ARxIUM is private and does not publish revenue. GetLatka estimates about 14.1 million dollars a year with 128 employees, and we use an estimated 15 million to 30 million dollars. It achieved HITRUST e1 certification in 2026.7,1
Ease of integration, 7.0: RIVA works with the Codonics Safe Label System to print barcode-verified labels matched to the hospital's drug database, and ARxIUM's inventory platform links to procurement systems.3,1
Each criterion is defined on our methodology page.
Who uses ARxIUM and what it's for
The buyer is a hospital or health system pharmacy that compounds IV syringes and bags in house and wants to cut manual compounding, waste, and outsourcing while meeting USP 797 and 800.3
Buyers should compare it with Equashield, Kiro Grifols, Omnicell, and Loccioni.
RIVA and the wider pharmacy line
RIVA prepares syringes and IV bags in a closed system, which ARxIUM says minimizes discarded doses and packaging, and it helps reduce waste through optimized batch sizes and extended beyond-use dating.3
FastPak Tabletop II, available from October 2026, makes up to 80 barcoded unit-dose packages a minute in a 4.5 square foot footprint. MedSelect Aspire dispensing cabinets and a MedSelect Anesthesia Station launched in December 2025.6,4
Deployments
Prinses Máxima Centrum marked one million sterile doses on RIVA in September 2026 after years of work with ARxIUM.4
ARxIUM works with customers and distributors worldwide from its headquarters in Canada and the United States.2,5
Pricing
ARxIUM does not publish prices for RIVA or its other systems; buyers request a consultation.1,3
Company, leadership, and revenue
ARxIUM has offices in Buffalo Grove, Illinois and Winnipeg, Manitoba. Nhat H. Ngo is chief executive.5,6
It does not publish revenue. GetLatka estimates about 14.1 million dollars with 128 employees in December 2025, so we use an estimated 15 million to 30 million dollars.7
Competitive landscape
| Company | Product | Pricing model | Deployment footprint | Where ARxIUM wins or loses |
|---|---|---|---|---|
| ARxIUM | RIVA IV robot plus packagers, cabinets, and inventory software3 | Not published; consultation1 | More than 19 million RIVA doses4 | IV robot plus pharmacy automation; consultation pricing; private |
| EQUASHIELD Pro | Automated hazardous drug compounder using closed transfer devices8 | Not published; quote8 | Equashield sells on five continents9 | EQUASHIELD Pro wins on closed transfer protection from start to finish. ARxIUM wins on one vendor for IV robots and wider pharmacy automation. |
| KIRO Oncology | Two-arm hazardous drug compounder with gravimetric checks10 | Not published; quote10 | Part of the inclusiv IV compounding portfolio15 | KIRO Oncology wins on gravimetric checks and self-cleaning. ARxIUM wins on one vendor for IV robots and wider pharmacy automation. |
| Omnicell | IVX Station robot inside the IV Compounding Service13 | Not published; service model13 | Hospitals, clinics, and care settings12 | Omnicell wins on a managed IV compounding service. ARxIUM wins on one vendor for IV robots and wider pharmacy automation. |
| Loccioni APOTECAchemo | APOTECAchemo IV chemotherapy compounding robot14 | Not published14 | User community across the US, Europe, the Gulf, and Asia14 | Loccioni wins on an established chemo compounding user community. ARxIUM wins on one vendor for IV robots and wider pharmacy automation. |
Limits
No published prices.1
Revenue is not published.7
RIVA is one product in a broad line, so buyers should check its roadmap and support directly.1
What customers say
Where it helps
An IV compounding robot plus packaging, dispensing, and inventory systems from one vendor.1,3
Where it falls short
Pricing only through a consultation.1
Leadership
ARxIUM does not publish leadership photos. Nhat H. Ngo is chief executive officer.6
Sources
- ARxIUM, homepage, accessed November 10, 2026
- ARxIUM, About us, accessed November 10, 2026
- ARxIUM, RIVA robotic IV automation and compounding systems, accessed November 10, 2026
- ARxIUM, News and events hub, accessed November 10, 2026
- ARxIUM, Our headquarters, accessed November 10, 2026
- National Law Review (EIN Presswire), ARxIUM announces commercial availability of FastPak Tabletop II (October 29, 2026), accessed November 10, 2026
- GetLatka, ARxIUM revenue estimate and employees (updated August 10, 2026), accessed November 10, 2026
- Equashield, EQUASHIELD Pro automated compounding of hazardous drugs, accessed November 10, 2026
- Nordic Capital, Equashield portfolio company profile, accessed November 10, 2026
- Kiro Grifols, KIRO Oncology, accessed November 10, 2026
- Grifols, Grifols reports revenues of EUR 7,524m, up 7% (February 26, 2026), accessed November 10, 2026
- Omnicell, homepage, accessed November 10, 2026
- Omnicell, IV compounding, accessed November 10, 2026
- Loccioni, Apoteca Community, accessed November 10, 2026
- Kiro Grifols, Robotic and other compounding devices, accessed November 10, 2026
- Omnicell, Fiscal year and fourth quarter 2025 financial results, accessed November 16, 2026

